Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

NCT02432963 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02432963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02432963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 14, 2016
Completion date
October 2, 2026
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, bladder carcinoma, colon carcinoma, estrogen receptor negative, head and neck squamous cell carcinoma, hepatocellular carcinoma, her2/neu negative, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, progesterone receptor negative, rectal carcinoma, renal cell carcinoma, soft tissue sarcoma, tp53 gene mutation, triple-negative breast carcinoma, unresectable solid neoplasm